Olympiad Research LP Sells 2,344 Shares of Illumina, Inc. $ILMN

Olympiad Research LP decreased its stake in Illumina, Inc. (NASDAQ:ILMN) by 50.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,308 shares of the life sciences company’s stock after selling 2,344 shares during the quarter. Olympiad Research LP’s holdings in Illumina were worth $220,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rise Advisors LLC grew its position in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 224 shares during the period. Parkside Financial Bank & Trust grew its position in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares in the last quarter. Cullen Frost Bankers Inc. bought a new stake in shares of Illumina during the 2nd quarter valued at $41,000. NewSquare Capital LLC raised its position in Illumina by 604.9% during the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after acquiring an additional 558 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 0.6%

Illumina stock opened at $120.67 on Friday. The firm’s fifty day moving average price is $102.84 and its 200-day moving average price is $95.86. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $153.06. The stock has a market cap of $18.44 billion, a P/E ratio of 15.27, a PEG ratio of 2.34 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. The business’s revenue for the quarter was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, Director Scott Gottlieb purchased 500 shares of Illumina stock in a transaction on Monday, November 3rd. The shares were acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the transaction, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of recent research reports. Daiwa America lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. Royal Bank Of Canada set a $124.00 price objective on shares of Illumina in a report on Tuesday, September 2nd. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Evercore ISI increased their price target on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Finally, Morgan Stanley lifted their target price on Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Monday, August 4th. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $115.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.